UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
or

Insmed Inc (INSM)

Insmed Inc (INSM)
78.31 -3.24 (-3.97%) 14:04 ET [NASDAQ]
78.06 x 200 78.37 x 110
Realtime by (Cboe BZX)
78.06 x 200 78.37 x 110
Realtime - - (-) -
Quote Overview for Mon, Mar 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
77.98
Day High
81.10
Open 80.90
Previous Close 81.55 81.55
Volume 737,804 737,804
Avg Vol 1,824,451 1,824,451
Stochastic %K 38.92% 38.92%
Weighted Alpha +34.10 +34.10
5-Day Change -1.86 (-2.32%) -1.86 (-2.32%)
52-Week Range 21.92 - 84.91 21.92 - 84.91
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 14,760,469
  • Shares Outstanding, K 180,999
  • Annual Sales, $ 363,710 K
  • Annual Income, $ -913,770 K
  • EBIT $ -873 M
  • EBITDA $ -853 M
  • 60-Month Beta 1.11
  • Price/Sales 39.34
  • Price/Cash Flow N/A
  • Price/Book 49.56

Options Overview Details

View History
  • Implied Volatility 47.32% ( +2.23%)
  • Historical Volatility 34.78%
  • IV Percentile 14%
  • IV Rank 3.88%
  • IV High 320.80% on 05/24/24
  • IV Low 36.27% on 11/06/24
  • Put/Call Vol Ratio 0.03
  • Today's Volume 38
  • Volume Avg (30-Day) 1,467
  • Put/Call OI Ratio 1.41
  • Today's Open Interest 39,280
  • Open Int (30-Day) 38,161

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.33
  • Number of Estimates 7
  • High Estimate -1.16
  • Low Estimate -1.47
  • Prior Year -1.06
  • Growth Rate Est. (year over year) -25.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.20 +2.59%
on 02/25/25
Period Open: 77.88
84.91 -7.94%
on 02/21/25
+0.29 (+0.37%)
since 02/03/25
3-Month
61.50 +27.11%
on 01/10/25
Period Open: 72.43
84.91 -7.94%
on 02/21/25
+5.74 (+7.92%)
since 12/03/24
52-Week
21.92 +256.61%
on 05/24/24
Period Open: 28.06
84.91 -7.94%
on 02/21/25
+50.11 (+178.58%)
since 03/01/24

Most Recent Stories

More News
Insmed: Q4 Earnings Snapshot

Insmed: Q4 Earnings Snapshot

INSM : 78.31 (-3.97%)
Goldman Sachs Sees High Merger Odds For This Large-Cap Biopharma In Trump 2.0 Era: Retail Has Been Alert

Insmed specializes in treatments for rare and serious diseases and is currently advancing its lead asset, brensocatib, a potential first-in-class therapy for bronchiectasis.

INSM : 78.31 (-3.97%)
1 Vanguard Index Fund to Buy to Beat the S&P 500 in 2025, According to a Wall Street Bank

Jefferies analysts have set the S&P 500 (SNPINDEX: ^GSPC) with a 2025 target of 6,000. That forecast implies about 1% downside from its current level of 6,050, which ranks among the most bearish outlooks...

PCVX : 73.07 (+0.07%)
JPM : 262.13 (-0.95%)
$SPX : 5,898.89 (-0.93%)
FTAI : 122.07 (-5.16%)
JEF : 65.31 (-1.34%)
SFM : 148.04 (-0.24%)
MLI : 80.94 (+0.95%)
GS : 615.16 (-1.15%)
INSM : 78.31 (-3.97%)
VTWO : 85.76 (-1.21%)
1 Vanguard Index Fund May Beat the S&P 500 by 100% in the Next Few Years, According to a Wall Street Analyst

In general, the S&P 500 (SNPINDEX: ^GSPC) is the preferred stock market barometer for large-cap companies, while the Russell 2000 is the preferred stock market barometer for small-cap companies. Specific...

PCVX : 73.07 (+0.07%)
JPM : 262.13 (-0.95%)
$SPX : 5,898.89 (-0.93%)
FTAI : 122.07 (-5.16%)
VOO : 542.31 (-0.74%)
SFM : 148.04 (-0.24%)
MLI : 80.94 (+0.95%)
GS : 615.16 (-1.15%)
INSM : 78.31 (-3.97%)
VTWO : 85.76 (-1.21%)
Insmed: Q3 Earnings Snapshot

Insmed: Q3 Earnings Snapshot

INSM : 78.31 (-3.97%)
Insmed: Q2 Earnings Snapshot

Insmed: Q2 Earnings Snapshot

INSM : 78.31 (-3.97%)
3 Small-Cap Stock ETFs Set to Surge if the Federal Reserve Cuts Rates

Amid a sector rotation into small-caps, Morgan Stanley is bullish on growth names ahead of the Fed's expected policy shift. Here's a look at three ETFs that can benefit.

VBK : 270.36 (-1.13%)
TRGP : 200.14 (-0.78%)
DECK : 139.03 (-0.24%)
AXON : 529.59 (+0.22%)
IWO : 272.49 (-1.56%)
BLK : 974.91 (-0.29%)
INSM : 78.31 (-3.97%)
FTAI : 122.07 (-5.16%)
SFM : 148.04 (-0.24%)
IJT : 131.39 (-0.79%)
$IQY : 1,350.10 (-1.00%)
ENSG : 130.94 (+1.39%)
A Russell 2000 Bull Market Is Coming: 1 Unstoppable Vanguard ETF to Buy Hand Over Fist

Small-cap stocks are on fire in July, but the Russell 2000 is still in a technical bear market.

MSFT : 394.00 (-0.75%)
AAPL : 241.72 (-0.05%)
NVDA : 116.85 (-6.46%)
CME : 256.81 (+1.20%)
INSM : 78.31 (-3.97%)
SFM : 148.04 (-0.24%)
ACLS : 55.71 (+1.68%)
RDFN : 6.27 (-6.00%)
BMBL : 4.95 (-4.81%)
DNUT : 6.24 (+0.48%)
TENB : 38.19 (+0.13%)
FTAI : 122.07 (-5.16%)
1 Historically Cheap Vanguard Index Fund to Buy Before It Soars 40%, According to a Wall Street Analyst

Tom Lee at Fundstrat Global Advisors believes cheap valuations and interest rate cuts will send the Russell 2000 much higher by the end of the summer.

INSM : 78.31 (-3.97%)
SFM : 148.04 (-0.24%)
FTAI : 122.07 (-5.16%)
JPM : 262.13 (-0.95%)
GS : 615.16 (-1.15%)
ANF : 99.90 (-3.00%)
FN : 195.62 (-2.21%)
$SPX : 5,898.89 (-0.93%)
VTWO : 85.76 (-1.21%)
3 Top ETFs to Add Small-Cap Stock Exposure

Seeking small-cap equity exposure as Fed rate-cut expectations start to rise? Here are three leading ETFs for small-cap stock investors.

BLK : 974.91 (-0.29%)
IJR : 110.76 (-0.92%)
$IQY : 1,350.10 (-1.00%)
FN : 195.62 (-2.21%)
ENSG : 130.94 (+1.39%)
SPSC : 135.09 (+1.42%)
IWM : 211.96 (-1.25%)
INSM : 78.31 (-3.97%)
FTAI : 122.07 (-5.16%)
PCVX : 73.07 (+0.07%)
VB : 234.84 (-1.16%)
TRGP : 200.14 (-0.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas...

See More

Key Turning Points

3rd Resistance Point 84.67
2nd Resistance Point 83.14
1st Resistance Point 82.35
Last Price 78.31
1st Support Level 80.03
2nd Support Level 78.50
3rd Support Level 77.71

See More

52-Week High 84.91
Last Price 78.31
Fibonacci 61.8% 60.85
Fibonacci 50% 53.42
Fibonacci 38.2% 45.98
52-Week Low 21.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements